Fuji Keizai published an outlook for 48 foreign-affiliated pharmaceutical companies, forecasting 2026 domestic prescription pharmaceutical sales of ¥4.2468 trillion, an increase of 7.7% year on year.
On the 21st, Fuji Keizai announced its forecast for 2026 domestic prescription pharmaceutical sales at 48 foreign-affiliated pharmaceutical companies.
The survey covered 48 foreign-affiliated pharmaceutical companies, and estimated the size of the market in 2026.
Domestic prescription pharmaceutical sales are forecast at ¥4.2468 trillion, representing a 7.7% year-on-year increase.